Correction: Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1)

Rheumatol Ther. 2024 May 16. doi: 10.1007/s40744-024-00673-2. Online ahead of print.

Authors

Hideto Kameda¹, Kohei Hagimori², Yoji Morisaki², Thorsten Holzkämper³, Ayako Konomi⁴, Hiroaki Dobashi⁵

Affiliations

¹ Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan.
² Eli Lilly Japan K.K., Kobe, Hyogo, Japan.
³ Eli Lilly and Company, Indianapolis, IN, USA.
⁴ Eli Lilly Japan K.K., Kobe, Hyogo, Japan. konomi_ayako@lilly.com.
⁵ Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan.

PMID: 38753272
DOI: 10.1007/s40744-024-00673-2

No abstract available

Publication types

Published Erratum